The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Belov B.S.

Nauchno-issledovatel'skiĭ institut revmatologii RAMN, Moskva

Sergeeva M.S.

Samara State Medical University, Samara, Russia

Tarasova G.M.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Bukhanova D.V.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

Vaccination in rheumatology: Evolution of views on the problem

Authors:

Belov B.S., Sergeeva M.S., Tarasova G.M., Bukhanova D.V.

More about the authors

Journal: Therapeutic Archive. 2017;89(5): 83‑89

DOI: 10.17116/terarkh201789583-89

Views: 2582

Downloaded: 1657

Download PDF (RU)
Contact the author
Table of contents

VACCINATION IN RHEUMATOLOGY: EVOLUTION OF VIEWS ON THE PROBLEM
VACCINATION IN RHEUMATOLOGY: EVOLUTION OF VIEWS ON THE PROBLEM

To cite this article:

Belov BS, Sergeeva MS, Tarasova GM, Bukhanova DV. Vaccination in rheumatology: Evolution of views on the problem. Therapeutic Archive. 2017;89(5):83‑89. (In Russ.)
https://doi.org/10.17116/terarkh201789583-89

МСФ на ЯМ
Close metadata
Recommended articles:
Risk factors of pulmonary cavi­tation in COVID-19 pneumonia. Piro­gov Russian Journal of Surgery. 2024;(5):36-42
Cavi­tary lung lesions in COVID-19 asso­ciated pneumonia: a single-center study of 40 cases. Piro­gov Russian Journal of Surgery. 2024;(6):28-35
«Masks» of CNS demye­linating diseases. Primary lymphoma. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(7-2):101-108
Microbial etiology of early-onset pneumonia in acute period of severe traumatic brain injury. Russian Journal of Anesthesiology and Reanimatology. 2024;(5):58-63
Coro­nary microvascular dysfunction in rheumatic diseases — what do we know today?. Russian Journal of Preventive Medi­cine. 2024;(9):138-143
Modern view on the possibilities of patients with rheumatoid arthritis remote treatment moni­toring. Russian Journal of Preventive Medi­cine. 2024;(11):40-45
Factors of adhe­rence to vaccination of the Arkhangelsk region adult popu­lation. Russian Journal of Preventive Medi­cine. 2024;(12):92-99
The resu­lts of the examination of patients with chro­nic gene­ralized periodontitis after novel coro­navirus infe­ction. Russian Journal of Stomatology. 2024;(4):18-22
Autoimmune diseases of central nervous system and respiratory viral infe­ctions in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):39-46
Central nervous system invo­lvement in systemic lupus erythematosus. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):124-129

The problem of coinfections that are due to both a rheumatic disease (RD) itself and the need to use immunosuppressive drugs deserves apparent attention in modern rheumatology. Coinfections substantially affect morbidity and mortality rates, especially in diffuse connective tissue diseases. The data available in the literature on the above subject matter suggest that vaccination is a powerful method for prevention of infectious diseases that are the most important problem for patients with RD.

Keywords:

autoimmune diseases
rheumatoid arthritis
systemic lupus erythematosus
coinfections
pneumonia
vaccination
pneumococcal vaccine

Authors:

Belov B.S.

Nauchno-issledovatel'skiĭ institut revmatologii RAMN, Moskva

Sergeeva M.S.

Samara State Medical University, Samara, Russia

Tarasova G.M.

FGBU "NII revmatologii im. V.A. Nasonovoĭ" RAMN, Moskva

Bukhanova D.V.

V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia

List of references:

  1. Ranjan P, Chakrawarty A, Kumari A, Kumar J. Immunization in Patients with Rheumatic Diseases: A Practical Guide for General Practitioners. J Clin Diagn Res. 2015;9(5):OE01-4. doi:10.7860/JCDR/2015/14147.5972
  2. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. Rheumatology (Oxford). 2007;46(7):1157-1160.
  3. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a largeprimary-care-derived cohort of patients with inflammatorypolyarthritis. Ann Rheum Dis. 2007;66(3):308-312.
  4. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis underanti-TNF-alpha therapy. Rheumatology (Oxford). 2003;42(5):617-621.
  5. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, Chan KA. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol. 2008;35(3):387-393.
  6. Wotton CJ, Goldacre MJ. Risk of invasive pneumococcal disease in people admitted to hospitalwith selected immune-mediated diseases: record linkage cohortanalyses. J Epidemiol Community Health. 2012;66(12):1177-1181. doi:10.1136/jech-2011-200168
  7. Polyanskaya MV. Pnevmoniya u patsientov s revmaticheskimi zabolevaniyami: chastota vstrechaemosti, klinicheskaya kartina, faktoryi riska: avtoref. dis. … kand. med. naukю M., 2009. (In Russ.)
  8. Pnevmo-23. Instruktsiya po primeneniyu, protivopokazaniya i sostav. Rezhim dostupa: http://www.rlsnet.ru/tn_index_id_249.htm (In Russ.)
  9. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis comparedwith controls: a population-based study. Arthritis Rheum. 2002;46(9):2287-2293.
  10. Koivuniemi R, Leirisalo-Repo M, Suomalainen R, Piirainen H, Paimela L. Infectious causes of death in patients with rheumatoid arthritis: an autopsy study. Scand J Rheumatol. 2006;35(4):273-276.
  11. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, Spitz PW, Haga M, Kleinheksel SM, Cathey MA. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994;37(4):481-494.
  12. Yazici Y, Curtis JR, Ince A, Baraf H, Malamet RL, Teng LL, Kavanaugh A. Efficacy of tocilizumab in patients with moderate to severe activerheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann Rheum Dis. 2012;71(2):198-205. doi:10.1136/ard.2010.148700
  13. Lanternier F, Henegar C, Mouthon L, Blanche P, Guillevin L, Launay O. Low influenza-vaccination rate among adults receivingimmunosuppressive therapy for systemic inflammatory disease. Ann Rheum Dis. 2008;67(7):1047. doi:10.1136/ard.2007.081703
  14. Pradeep J, Watts R, Clunie G. Audit on the uptake of influenza and pneumococcal vaccination in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(6):837-838.
  15. Dougados M1, Soubrier M, Antunez A, Balint P, Balsa A, Buch MH, Casado G, Detert J, El-Zorkany B, Emery P, Hajjaj-Hassouni N, Harigai M, Luo SF, Kurucz R, Maciel G, Mola EM, Montecucco CM, McInnes I, Radner H, Smolen JS, Song YW, Vonkeman HE, Winthrop K, Kay J. Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study(COMORA). Ann Rheum Dis. 2014;73(1):62-68. doi:10.1136/annrheumdis-2013-204223
  16. Medunitsyin NV. Vaktsinologiya. 2-e izd., pererab. i dop. M.: Triada-H; 2004. (In Russ.)
  17. Kuroda Y, Nacionales DC, Akaogi J, Reeves WH, Satoh M. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother. 2004;58(5):325-337.
  18. Bach JF. Protective role of infections and vaccinations on autoimmune diseases. J Autoimmun. 2001;16(3):347-353.
  19. Levitsky LL. Childhood immunizations and chronic illness. N Engl J Med. 2004;350(14):1380-1382.
  20. Brodman R, Gilfillan R, Glass D, Schur PH. Influenzal vaccine response in systemic lupus erythematosus. Ann Intern Med. 1978;88(6):735-740.
  21. Herron A, Dettleff G, Hixon B, Brandwin L, Ortbals D, Hornick R, Hahn B. Influenza vaccination in patients with rheumatic diseases. Safety and efficacy. JAMA. 1979;242(1):53-56.
  22. Louie JS, Nies KM, Shoji KT, Fraback RC, Abrass C, Border W, Cherry JD, Imagawa D. Clinical and antibody responses after influenza immunization in systemic lupus erythematosus. Ann Intern Med. 1978;88(6):790-792.
  23. Ristow SC, Douglas RG Jr, Condemi JJ. Influenza vaccination of patients with systemic lupus erythematosus. Annals of internal medicine. 1978;88(6):786-789.
  24. Williams GW, Steinberg AD, Reinertsen JL, Klassen LW, Decker JL, Dolin R. Influenza immunization in systemic lupus eruthematosus. A double-blind trial. Ann Intern Med. 1978;88(6):729-734.
  25. Croft SM, Schiffman G, Snyder E, Herrmann K, James K, Jarrett MP. Specific antibody response after in vivo antigenic stimulation in systemic lupus erythematosus. J Rheumatol. 1984;11(2):141-146.
  26. Battafarano DF, Battafarano NJ, Larsen L, Dyer PD, Older SA, Muehlbauer S, Hoyt A, Lima J, Goodman D, Lieberman M, Enzenauer RJ. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum. 1998;41(10):1828-1834.
  27. Mercado U. Why have rheumatologists been reluctant to vaccinate patients with systemic lupus erythematosus? The Journal of rheumatology. 2006;33(8):1469-1471.
  28. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritisreceiving adalimumab. J Rheumatol. 2007;34(2):272-279.
  29. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):106-111.
  30. Mori S, Ueki Y, Akeda Y, Hirakata N, Oribe M, Shiohira Y, Hidaka T, Oishi K. Pneumococcal polysaccharide vaccination in rheumatoid arthritispatients receiving tocilizumab therapy. Ann Rheum Dis. 2013;72(8):1362-1366. doi:10.1136/annrheumdis-2012-202658
  31. Bingham CO 3rd, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62(1):64-74. doi:10.1002/art.25034
  32. Hua C, Barnetche T, Combe B, Morel J. Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016-1026. doi:10.1002/acr.22246
  33. Kapetanovic M, Saxne T, Jönsson G, Truedsson L, Geborek P. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R171. doi:10.1186/ar4358
  34. Schiff M. Response to pneumococcal vaccine in rheumatoid arthritis patients with an inadequate response to anti-TNF therapy treated with abatacept in the arrive trial. Annals of the rheumatic diseases. 2007;66(Suppl.II):437.
  35. Pham T. Abatacept therapy and safety management Joint, bone, spine: revue du rhumatisme. 2009;76(Suppl.1):3-84.
  36. Winthrop KL, Silverfield J, Racewicz A, Neal J, Lee EB, Hrycaj P, Gomez-Reino J, Soma K, Mebus C, Wilkinson B, Hodge J, Fan H, Wang T, Bingham CO 3rd. The effect of tofacitinib on pneumococcal and influenza vaccineresponses in rheumatoid arthritis. Ann Rheum Dis. 2016;75(4):687-695. doi:10.1136/annrheumdis-2014-207191
  37. Crnkic Kapetanovic M, Saxne T, Truedsson L, Geborek P. Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritistreated with different antirheumatic drugs. Arthritis Res Ther. 2013;15(1):R1. doi:10.1186/ar4127
  38. Plotkin SA. Correlates of protection induced by vaccination. Clinical and vaccine immunology. 2010;17(7):1055-1065.
  39. Kavanaugh A. Infection prophylaxis in antirheumatic therapy: emphasis on vaccination. Curr Opin Rheumatol. 2009;21(4):419-424. doi:10.1097/BOR.0b013e328329ec6e
  40. van Assen S, Agmon-Levin N, Elkayam O, Cervera R, Doran MF, Dougados M, Emery P, Geborek P, Ioannidis JP, Jayne DR, Kallenberg CG, Müller-Ladner U, Shoenfeld Y, Stojanovich L, Valesini G, Wulffraat NM, Bijl M. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2011;70(3):414-422. doi:10.1136/ard.2010.137216
  41. Binymin K, Cooper RG. Late reactivation of spinal tuberculosis by low-dose methotrexatetherapy in a patient with rheumatoid arthritis. Rheumatology (Oxford). 2001;40(3):341-342.
  42. McMahan ZH, Bingham CO 3rd. Effects of biological and non-biological immunomodulatory therapieson the immunogenicity of vaccines in patients with rheumaticdiseases. Arthritis Res Ther. 2014;16(6):506. doi:10.1186/s13075-014-0506-0
  43. Salemi S, D'Amelio R. Are anti-infetious vaccinations safe and effective in patients with autoimmunity? Int Rev Immunol. 2010;29(3):270-314. doi:10.3109/08830185.2010.483028
  44. Bengtsson C, Kapetanovic MC, Källberg H, Sverdrup B, Nordmark B, Klareskog L, Alfredsson L; EIRA Study Group. Common vaccinations among adults do not increase the risk of developing rheumatoid arthritis: results from the Swedish EIRA study. Ann Rheum Dis. 2010;69(10):1831-1833. doi:10.1136/ard.2010.129908
  45. Kostinov MP, Tarasova AA. Vaktsinoprofilaktika pnevmokokkovoy infektsii i grippa pri autoimmunnyih zabolevaniyah. M.: MDB; 2009. (In Russ.)
  46. Naumtseva MS. Otsenka immunogennosti i bezopasnosti 23-valentnoy polisaharidnoy pnevmokokkovoy vaktsinyi u bolnyih revmatoidnyim artritom: avtoref. dis. … kand. med. Nauk. M.; 2016. (In Russ.)
  47. Bijl M, Agmon-Levin N, Dayer JM, Israeli E, Gatto M, Shoenfeld Y. Vaccination of patients with auto-immune inflammatory rheumaticdiseases requires careful benefit-risk assessment. Autoimmun Rev. 2012;11(8):572-576. doi:10.1016/j.autrev.2011.10.015
  48. Ferreira I, Isenberg D. Vaccines and biologics. Annals of the rheumatic diseases. 2014;73(8):1446-1454.
  49. Perry LM, Winthrop KL, Curtis JR. Vaccinations for rheumatoid arthritis Current rheumatology reports. 2014;16(8):431.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.